文章名稱引用次數(shù)

• Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy23
• Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma16
• An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT8
• CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy8
• Altered fecal bacterial composition correlates with disease activity in inflammatory bowel disease and the extent of IL8 induction8
• High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma7
• Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)6
• Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology5
• Celyad's novel CAR T-cell therapy for solid malignancies5
• Epstein-Barr virus infection in gliomas4